The first 60 days: Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Blastic plasmacytoid dendritic cell neoplasm is a rare aggressive blood cancer of dendritic-cell precursors, a few hundred US cases a year, that often first appears as bruise-like skin lesions. Two CD123-directed drugs, tagraxofusp and pivekimab sunirine, are the first targeted therapies; allogeneic transplant in first remission is still the only route to long-term control. Below, week by week, is what OnCo's record of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- Medical oncologistNamed in the standard of care for: First line, Consolidation, Relapsed.
- Transplant and cell therapy teamNamed in the standard of care for: Consolidation.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Tagraxofusp (monitor albumin for capillary leak) or pivekimab sunirine (2026); alternatives hyper-CVAD or venetoclax-based regimens; CNS prophylaxis.
Allogeneic HSCT in first complete remission for eligible patients; autologous transplant in selected cases (Japanese data).
- 3.Relapsed
Alternative CD123 agent, venetoclax combinations, clinical trials; prognosis poor.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example CD123, CD4, CD56, TCF4, TCL1 immunophenotype, Absence of MPO, lysozyme, CD3, MYC rearrangement, TET2, ASXL1, ZRSR2 mutations, CSF examination), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Skin-only presentation, Leukaemic / marrow-involving disease, Cases arising with or from CMML/MDS.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
First line
- For my situation (first line), which of the standard options do you recommend and why?Guideline options include: Tagraxofusp (monitor albumin for capillary leak) or pivekimab sunirine (2026); alternatives hyper-CVAD or venetoclax-based regimens; CNS prophylaxis.
- Am I a candidate for Tagraxofusp, Pivekimab sunirine, Venetoclax, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Consolidation
- For my situation (consolidation), which of the standard options do you recommend and why?Guideline options include: Allogeneic HSCT in first complete remission for eligible patients; autologous transplant in selected cases (Japanese data).
Relapsed
- For my situation (relapsed), which of the standard options do you recommend and why?Guideline options include: Alternative CD123 agent, venetoclax combinations, clinical trials; prognosis poor.
- Am I a candidate for Venetoclax, Pivekimab sunirine, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Pivekimab sunirine, Venetoclax, Allogeneic stem cell transplantation?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “No randomised trials; sequencing of CD123 agents unknown”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Capillary leak syndrome with tagraxofusp”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the full pageBlastic plasmacytoid dendritic cell neoplasm is a rare aggressive blood cancer of dendritic-cell precursors, a few hundred US cases a year, that often first appears as bruise-like skin lesions. Two CD123-directed drugs, tagraxofusp and pivekimab sunirine, are the first targeted therapies; allogeneic transplant in first remission is still the only route to long-term control.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Rare cancers: Rare cancers are those with fewer than about 6 new cases per 100,000 people per year.
Every term links to the glossary.